Dereck Tait

2.7k total citations
23 papers, 1.0k citations indexed

About

Dereck Tait is a scholar working on Epidemiology, Infectious Diseases and Immunology. According to data from OpenAlex, Dereck Tait has authored 23 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Epidemiology, 12 papers in Infectious Diseases and 5 papers in Immunology. Recurrent topics in Dereck Tait's work include Tuberculosis Research and Epidemiology (9 papers), Mycobacterium research and diagnosis (7 papers) and Hepatitis C virus research (5 papers). Dereck Tait is often cited by papers focused on Tuberculosis Research and Epidemiology (9 papers), Mycobacterium research and diagnosis (7 papers) and Hepatitis C virus research (5 papers). Dereck Tait collaborates with scholars based in South Africa, United Kingdom and United States. Dereck Tait's co-authors include Karl R. Beutner, Grégory Mertz, Oliver N. Keene, Lawrence Corey, Stephen L. Sacks, Jorma Paavonen, Anna Wald, John M. Douglas, Terri Warren and Mauricio Vargas‐Cortes and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Dereck Tait

22 papers receiving 953 citations

Peers

Dereck Tait

EPIDE

IMMUN

MICRO

RHEUM

Lily Yin Weckx Brazil

Judy Zeh United States

Olivier Godeaux Belgium

Sylvia Berry United States

Sheena Sutherland United Kingdom

Karen E. Mark United States

Michael Remington United States

Mauricio Vargas‐Cortes United States

Himal Lal Belgium

Kimmo Linnavuori Finland

Lily Yin Weckx Brazil

Dereck Tait

1.1k ×1.8

EPIDE

353 ×0.9

250 ×1.4

IMMUN

126 ×1.4

MICRO

88 ×1.0

RHEUM

Citations per year, relative to Dereck Tait Dereck Tait (= 1×) peers Lily Yin Weckx

Countries citing papers authored by Dereck Tait

Since Specialization

Citations

This map shows the geographic impact of Dereck Tait's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dereck Tait with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dereck Tait more than expected).

Fields of papers citing papers by Dereck Tait

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dereck Tait. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dereck Tait. The network helps show where Dereck Tait may publish in the future.

Co-authorship network of co-authors of Dereck Tait

This figure shows the co-authorship network connecting the top 25 collaborators of Dereck Tait. A scholar is included among the top collaborators of Dereck Tait based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dereck Tait. Dereck Tait is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chuang, Wan‐Long, Anchalee Avihingsanon, Chi-Yi Chen, et al.. (2025). LBP-004 Primary analysis of a phase 2b open-label study demonstrates VTP-300 administered with low-dose nivolumab is associated with meaningful reductions of HBsAg in chronic hepatitis B participants with HBsAg less than 200 IU/mL. Journal of Hepatology. 82. S71–S71.

Tait, Dereck, Andreas H. Diacon, Álvaro H. Borges, et al.. (2024). Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized Trial. The Journal of Infectious Diseases. 230(5). 1262–1270. 6 indexed citations

García‐Basteiro, Alberto L., Richard G. White, Dereck Tait, et al.. (2022). End-point definition and trial design to advance tuberculosis vaccine development. European Respiratory Review. 31(164). 220044–220044. 12 indexed citations

Jayawardana, Sahan, Chathika K. Weerasuriya, Janet Seeley, et al.. (2022). Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis. npj Vaccines. 7(1). 138–138. 7 indexed citations

Jeremiah, Kidola, Christian Ritz, George PrayGod, et al.. (2021). Prevalence of Mycobacterium tuberculosis infection as measured by the QuantiFERON-TB Gold assay and ESAT-6 free IGRA among adolescents in Mwanza, Tanzania. PLoS ONE. 16(6). e0252808–e0252808. 8 indexed citations

Williams, Ann, Bernard Fritzell, Dominick J. Laddy, et al.. (2020). The TB vaccine development pathway – An innovative approach to accelerating global TB vaccine development. Tuberculosis. 126. 102040–102040. 8 indexed citations

DeVincenzo, John P., Dereck Tait, John Efthimiou, et al.. (2019). A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein. Antimicrobial Agents and Chemotherapy. 64(2). 56 indexed citations

Suliman, Sara, Angelique Kany Kany Luabeya, Hennie Geldenhuys, et al.. (2018). Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial. American Journal of Respiratory and Critical Care Medicine. 199(2). 220–231. 76 indexed citations

Evans, Thomas G., Gavin Churchyard, Adam Penn‐Nicholson, et al.. (2016). Epidemiologic studies and novel clinical research approaches that impact TB vaccine development. Tuberculosis. 99. S21–S25. 4 indexed citations

10.

Ellis, Ruth D., Mark Hatherill, Dereck Tait, et al.. (2015). Innovative clinical trial designs to rationalize TB vaccine development. Tuberculosis. 95(3). 352–357. 23 indexed citations

11.

Gane, E., Graham R. Foster, J Cianciara, et al.. (2010). 2003 ANTIVIRAL ACTIVITY, PHARMACOKINETICS, AND TOLERABILITY OF AZD7295, A NOVEL NS5A INHIBITOR, IN A PLACEBO-CONTROLLED MULTIPLE ASCENDING DOSE STUDY IN HCV GENOTYPE 1 AND 3 PATIENTS. Journal of Hepatology. 52. S464–S464. 14 indexed citations

12.

Corey, Lawrence, Anna Wald, Stephen L. Sacks, et al.. (2004). Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes. Obstetrical & Gynecological Survey. 59(4). 260–261. 36 indexed citations

13.

Corey, Lawrence, Anna Wald, Raj Patel, et al.. (2003). Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes. New England Journal of Medicine. 350(1). 11–20. 463 indexed citations

14.

Loizou, S., et al.. (1997). Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis & Rheumatism. 40(1). 103–108. 114 indexed citations

15.

Tait, Dereck, et al.. (1996). Hepatitis C virus infection in chronic liver disease in Natal.. PubMed. 86(1). 80–3. 7 indexed citations

16.

Tait, Dereck, et al.. (1993). Hepatitis C virus antibodies among risk groups in a South African area endemic for hepatitis B virus. Journal of Medical Virology. 40(1). 65–68. 25 indexed citations

17.

Karim, Salim S. Abdool & Dereck Tait. (1993). Hepatitis C virus infection in urban and rural Natal/KwaZulu.. PubMed. 83(3). 191–3. 4 indexed citations

18.

Bill, P.L.A., et al.. (1992). Adult T-cell leukaemia/lymphoma associated with HTLV-I in Natal.. PubMed. 81(10). 528–9. 7 indexed citations

19.

Livingston, Mark, et al.. (1990). A double‐blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia. Acta Psychiatrica Scandinavica. 82(S358). 136–137. 15 indexed citations

20.

McCreadie, Robin G., Norman A. Todd, Mark Livingston, et al.. (1988). A double blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia. Acta Psychiatrica Scandinavica. 78(1). 49–56. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact